Some protocols call for twice-daily dosing, splitting the total daily amount into morning and evening administrations
It is strictly designated for laboratory research only and is not approved for human or animal administration
Vitamin B12 or folate deficiency anaemia Diagnosis NHS
One should not use AOD-9604 if they: Are pregnant or breastfeeding Are a minor Have a current or recent history of cancer (particularly hormone-sensitive cancers) Have uncontrolled diabetes or significant insulin resistance Have active thyroid disease that is not well-managed Are taking medications that may interact with peptide therapy (discuss with your provider) Have a known hypersensitivity to peptide compounds Comprehensive labs including metabolic panel, fasting glucose, HbA1c, thyroid panel, lipid panel, and hormone levels should be run before starting any peptide therapy and monitored regularly throughout
Treatment of Leber's optic atrophy
A 2024 review in Cartilage identified AOD-9604 among key peptides recognized for benefits to bone and joint health, noting its capacity for chondrogenic induction and cartilage regeneration in osteoarthritis models
